- Home
- DSY vs PYXS Comparison
DSY vs PYXS Comparison
Compare DSY & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- PYXS
- Stock Information
- Founded
- DSY 2020
- PYXS 2018
- Country
- DSY China
- PYXS United States
- Employees
- DSY N/A
- PYXS N/A
- Industry
- DSY
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- PYXS Health Care
- Exchange
- DSY Nasdaq
- PYXS Nasdaq
- Market Cap
- DSY 198.6M
- PYXS 210.4M
- IPO Year
- DSY N/A
- PYXS 2021
- Fundamental
- Price
- DSY $5.58
- PYXS $3.23
- Analyst Decision
- DSY
- PYXS Strong Buy
- Analyst Count
- DSY 0
- PYXS 6
- Target Price
- DSY N/A
- PYXS $9.00
- AVG Volume (30 Days)
- DSY 352.0K
- PYXS 456.9K
- Earning Date
- DSY 11-10-2024
- PYXS 11-05-2024
- Dividend Yield
- DSY N/A
- PYXS N/A
- EPS Growth
- DSY N/A
- PYXS N/A
- EPS
- DSY 11.99
- PYXS N/A
- Revenue
- DSY $7,984,260.00
- PYXS $16,146,000.00
- Revenue This Year
- DSY N/A
- PYXS N/A
- Revenue Next Year
- DSY N/A
- PYXS N/A
- P/E Ratio
- DSY $0.46
- PYXS N/A
- Revenue Growth
- DSY 224.34
- PYXS N/A
- 52 Week Low
- DSY $0.75
- PYXS $1.35
- 52 Week High
- DSY $13.47
- PYXS $6.85
- Technical
- Relative Strength Index (RSI)
- DSY 60.61
- PYXS 40.94
- Support Level
- DSY $3.61
- PYXS $3.11
- Resistance Level
- DSY $6.82
- PYXS $3.42
- Average True Range (ATR)
- DSY 1.44
- PYXS 0.16
- MACD
- DSY 0.17
- PYXS -0.02
- Stochastic Oscillator
- DSY 71.64
- PYXS 32.86
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven and technology-empowered company devoted to the development, production and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pad and other feminine hygiene products. Through the platform, It focuses on high-quality product development, deep customer engagement and efficient sales and marketing.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.